The Tel Aviv Stock Exchange (TASE) indices were mixed today. The Tel Aviv 25 index edged down 0.02% to 524.41 points, the Tel Aviv 100 edged up 0.1% to 569.27 points, and the Tel-Tech rose 0.38% to 434.1 points. Turnover was NIS 617.2 million.
The TASE had an odd session today. The market opened briskly thanks to rises on Wall Street and Minister of Finance Benjamin Netanyahu's announcement of tax cuts; the main indices rose about 1%.
But as the day wore on, the upward momentum leveled off, and then reversed, returning the indices back to their starting points. Technical analysts blamed the change in direction on the Tel Aviv 25 index reaching the 530-point resistance level, a level it is apparently unable to breach.
The downward pressure intensified toward the end of the session, completely erasing the Tel Aviv 25 index's earlier gain, although it was up 2.7% for the week.
Agis for sale or not?
Early last week, "Globes" reported an assessment that Barr Laboratories Inc. (NYSE:BRL), the world's fifth largest generic drug maker, might acquire Agis Industries (TASE:AGIS). "Globes" quoted an analyst who based his assessment on a statement by Barr that it wanted to enter the dermatology market - Agis's main business, and that the two companies already collaborate - factors that might pave the way to an acquisition.
This morning, "Ha'aretz" reported that Agis president and chairman Moshe (Mory) Arkin was negotiating to sell the company's pharmaceutical and active pharmaceutical ingredients (API) businesses to Barr Laboratories for $900 million. Agis's share responded to the report by plummeting until the TASE decided to suspend trading in it at 11:30 am, by which time it was down 4% on a huge turnover of NIS 64 million, triple its daily average, in less than two hours.
Agis claimed that it was unable to get hold of either Arkin or Agis CEO Refael Lebel, who are in the US, until 1:25 pm. Only then did Agis issue a statement denying the report. All that Agis was willing to state was that it was holding preliminary talks for a merger with a "major international generic drug company", without disclosing the name of the company, or any other details.
Investors did not like the fog that descended on Agis at all, and sent the share down 5.7% on a turnover of NIS 122 million, the day's largest.
A new competitor for Teva
Although it opened with a 0.8% positive arbitrage gap, Teva Pharmaceuticals (Nasdaq: TEVA; TASE:TEVA) fell 0.2% today on a large NIS 80 million turnover.
The weakness was apparently due to the publication of GlaxoSmithKline's (NYSE; LSE:GSK) financial reports today that stated that it was suing Teva for violating its patent on an API for its diabetes treatment, which has $1.7 billion in sales a year. The chances of the lawsuit are uncertain, but the effect on Teva's share was obvious today.
I was given another reason for Teva's weakness: the entry of a new competitor for generic Purinethol, a leukemia treatment. Teva received exclusive manufacturing rights to generic Purinethol from Glaxo last July, under an agreement settling all pending lawsuits between the parties over patents to Nabumetone, a generic version of Glaxo's ethical Relafen. The agreement included Teva's lawsuit against Glaxo for violating antitrust laws on the matter.
Yesterday, the US Food and Drug Administration granted immediate distribution right for generic Purinethol to Par Pharmaceutical's (NYSE:PRX) partner. Generic Purinethol has $90 million in sales a year. It is predicted that the entry of the new competitor will cost Teva $40 million in sales and $10-15 million in net profits a year.
Retalix (Nasdaq: RTLX; TASE:RTLX) published its fourth quarter and full-year 2003 financial report today. It showed further growth in revenue and profits. Retalix responded positively, rising 2% in lively trading.
El Al (TASE:ELAL) also continues to rise in lively trading. The airline also continued its tradition of leaking its financial report before the official publication date (on March 3, this year). Recent reports claim that El Al is expected to show a substantial improvement for the fourth quarter, and that it will break even or lose no more than $2 million for 2003 as a whole.
El Al has risen 20% in lively trading in recent days. The trend continued today, and the share rose 5.7% on a turnover of almost NIS 5 million.
I will conclude with three well-performing shares. Granite Hacarmel Investments (TASE:GRNT) jumped 8.5% on a huge turnover following a "Globes" report yesterday that it planned to float its core subsidiaries, Sonol, Supergas Tambour, and Tambour Ecology.
Food retailers reacted to Minister of Finance Benjamin Netanyahu's VAT cut announcement, intended to encourage consumption, which will contribute to their revenues. Food retailers have been hard hit by the recession during the past couple of years. Super Sol (NYSE: SAE; TASE:SAE) rose 2.6% today and Blue Square Israel (NYSE: BSI; TASE:BSI) rose 5.2%.
Published by Globes [online] - www.globes.co.il - on February 12, 2004